Natera stock has delivered a very large 3 year gain while the current valuation checks lean expensive, so investors now face a gap between strong past returns and a low overall value score.

• Over the past 3 years, Natera has returned about 4.7x, which sets a high bar for any further upside to be justified by fundamentals.
• Progress in areas like the Signatera and Prospera testing portfolios can support expectations for future revenue, but those expectations may be sensitive to changes in reimbursement policy, competitive tests or clinical adoption rates.
• With the stock only scoring 2 out of 6 on broader valuation checks, Natera does not screen as a clear bargain on Simply Wall St's framework.

The issue now is whether Natera's current share price still offers an attractive trade off between its growth story and the valuation implied by this low score.

Is Natera Getting Expensive on Sales?

P/S is a useful lens for Natera because the company is more focused on building its testing volume and revenue base than on current earnings.

Natera currently trades on a P/S of about 15.0x, which is above both the broader biotech industry average of roughly 10.8x and the peer average of about 11.9x. On Simply Wall St's framework, a more tailored fair P/S ratio for Natera, based on its profile and risks, is closer to 9.6x. This represents a sizeable gap between what the model suggests might be reasonable and what the market is currently willing to pay.

Despite recent headlines around Signatera's performance data and expanded Prospera coverage, the share price already reflects a richer revenue multiple than typical biotech peers and the model's fair ratio.

On this P/S measure, Natera stock appears overvalued, with investors paying a clear premium to both peers and the modelled fair multiple for each dollar of revenue.

The Natera Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Natera pick up where this valuation puzzle leaves off by spelling out which combinations of growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than today's price. Rather than focusing on a single multiple or model line, each narrative lays out the assumptions behind its fair value so you can compare them with Natera's actual results over time, and they sit within Simply Wall St's Community page.

The community is split on Natera, with one side focused on long runway in testing volumes and the other worried about what tighter regulation and reimbursement could mean.

Bull case: 7% undervalued

"Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, underpinning future revenue expansion…"

Bear case: 27% overvalued

"Natera is likely to face significant headwinds from tightening regulatory scrutiny and evolving healthcare policies in the US and Europe, which could delay new product approvals, increase compliance costs, and restrict reimbursement for existing and upcoming tests, putting long-term revenue growth at risk…"

Do you think there's more to the story for Natera? Head over to our Community to see what others are saying!

The Bottom Line

Natera now trades on a clear revenue premium, so the market-multiple view points to the stock being overvalued rather than obviously mispriced. That does not rule out further upside, but it does mean expectations around future testing volumes, reimbursement and regulatory outcomes are already doing a lot of work. From here, the key question is whether Natera can translate its testing portfolio into durable revenue and margin progress that keeps justifying this richer multiple, or whether sentiment cools and the valuation settles closer to peers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.